IL151788A0 - Oxazolidinone tablet formulation - Google Patents

Oxazolidinone tablet formulation

Info

Publication number
IL151788A0
IL151788A0 IL15178801A IL15178801A IL151788A0 IL 151788 A0 IL151788 A0 IL 151788A0 IL 15178801 A IL15178801 A IL 15178801A IL 15178801 A IL15178801 A IL 15178801A IL 151788 A0 IL151788 A0 IL 151788A0
Authority
IL
Israel
Prior art keywords
oxazolidinone
tablet formulation
formulation
tablet
oxazolidinone tablet
Prior art date
Application number
IL15178801A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL151788(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL151788A0 publication Critical patent/IL151788A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL15178801A 2000-03-22 2001-03-15 Oxazolidinone tablet formulation IL151788A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19096900P 2000-03-22 2000-03-22
PCT/US2001/005812 WO2001070225A2 (en) 2000-03-22 2001-03-15 Oxazolidinone tablet formulation

Publications (1)

Publication Number Publication Date
IL151788A0 true IL151788A0 (en) 2003-04-10

Family

ID=22703542

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15178801A IL151788A0 (en) 2000-03-22 2001-03-15 Oxazolidinone tablet formulation

Country Status (33)

Country Link
EP (1) EP1265608B1 (zh)
JP (1) JP2003527424A (zh)
KR (2) KR20070094673A (zh)
CN (1) CN1208058C (zh)
AR (1) AR033357A1 (zh)
AT (1) ATE412413T1 (zh)
AU (2) AU4324301A (zh)
BG (1) BG107117A (zh)
BR (1) BR0108846A (zh)
CA (1) CA2400118A1 (zh)
CZ (1) CZ20023133A3 (zh)
DE (1) DE60136341D1 (zh)
DK (1) DK1265608T3 (zh)
EA (1) EA006772B1 (zh)
EC (1) ECSP013979A (zh)
ES (1) ES2312422T3 (zh)
HK (1) HK1054325B (zh)
HR (1) HRP20020765A2 (zh)
HU (1) HUP0300378A3 (zh)
IL (1) IL151788A0 (zh)
MX (1) MXPA02009316A (zh)
MY (1) MY136370A (zh)
NO (1) NO20024505L (zh)
NZ (1) NZ521525A (zh)
PE (2) PE20011126A1 (zh)
PL (1) PL201686B1 (zh)
PT (1) PT1265608E (zh)
SK (1) SK12092002A3 (zh)
TW (1) TWI293028B (zh)
UA (1) UA77654C2 (zh)
WO (1) WO2001070225A2 (zh)
YU (1) YU69802A (zh)
ZA (1) ZA200207073B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CN101262853A (zh) * 2005-07-20 2008-09-10 特瓦制药工业有限公司 包括利奈唑胺晶型iv的稳定的药物组合物
WO2010026597A1 (en) * 2008-09-02 2010-03-11 Hetero Research Foundation Oral dosage forms of linezolid and processes for their preparation
PT2642996T (pt) * 2010-11-24 2020-12-30 Melinta Subsidiary Corp Composições farmacêuticas
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103505459B (zh) * 2012-06-20 2016-02-24 北京万生药业有限责任公司 利奈唑胺药物组合物
CN104622831B (zh) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 一种口服片剂及其制备方法
MX2017012460A (es) 2015-04-01 2018-01-30 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de la anemia.
CN106727396A (zh) * 2016-11-22 2017-05-31 湖北广济药业股份有限公司 一种ⅱ晶型利奈唑胺片及其制备方法
CN109481412A (zh) * 2018-08-17 2019-03-19 扬子江药业集团北京海燕药业有限公司 一种ii晶型利奈唑胺片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
CA2372233A1 (en) * 1999-05-27 2000-12-07 Pharmacia & Upjohn Company Bicyclic oxazolidinones as antibacterial agent

Also Published As

Publication number Publication date
PE20020499Z (es) 2002-07-12
DK1265608T3 (da) 2008-12-08
CZ20023133A3 (cs) 2003-01-15
EA006772B1 (ru) 2006-04-28
YU69802A (sh) 2005-11-28
BR0108846A (pt) 2003-05-06
WO2001070225A3 (en) 2001-12-13
PL366067A1 (en) 2005-01-24
CN1208058C (zh) 2005-06-29
ATE412413T1 (de) 2008-11-15
BG107117A (bg) 2003-05-30
TWI293028B (en) 2008-02-01
KR100786410B1 (ko) 2007-12-17
HRP20020765A2 (en) 2003-12-31
PL201686B1 (pl) 2009-04-30
PT1265608E (pt) 2008-12-15
EA200201006A1 (ru) 2003-02-27
CA2400118A1 (en) 2001-09-27
DE60136341D1 (de) 2008-12-11
ECSP013979A (es) 2002-01-25
MY136370A (en) 2008-09-30
WO2001070225A2 (en) 2001-09-27
CN1418097A (zh) 2003-05-14
NO20024505D0 (no) 2002-09-20
EP1265608B1 (en) 2008-10-29
AU2001243243B2 (en) 2004-10-14
HK1054325A1 (en) 2003-11-28
UA77654C2 (en) 2007-01-15
HUP0300378A3 (en) 2004-11-29
AU4324301A (en) 2001-10-03
ES2312422T3 (es) 2009-03-01
HK1054325B (zh) 2006-01-13
KR20020083185A (ko) 2002-11-01
PE20011126A1 (es) 2001-10-31
KR20070094673A (ko) 2007-09-20
HUP0300378A2 (hu) 2003-06-28
JP2003527424A (ja) 2003-09-16
ZA200207073B (en) 2003-12-03
NO20024505L (no) 2002-09-20
NZ521525A (en) 2004-02-27
SK12092002A3 (sk) 2002-12-03
AR033357A1 (es) 2003-12-17
EP1265608A2 (en) 2002-12-18
MXPA02009316A (es) 2004-04-05

Similar Documents

Publication Publication Date Title
EG24074A (en) Formulation
GB0000891D0 (en) Formulation
GB0025611D0 (en) Tablet inserters
IL151788A0 (en) Oxazolidinone tablet formulation
GB0003806D0 (en) Tablet dispenser
GB0014851D0 (en) Novel pharmaceutical formulation
GB0005382D0 (en) Pharmaceutical composition
GB0014883D0 (en) Novel pharmaceutical formulation
GB0014892D0 (en) Novel pharmaceutical formulation
GB0014947D0 (en) Novel pharmaceutical formulation
HK1054508A1 (zh) 新型製劑
GB0021487D0 (en) Pharmaceutical
EP1414417A4 (en) PHARMACEUTICAL FORMULATION
GB0014869D0 (en) Novel pharmaceutical formulation
CA89374S (en) Tablet
CA89992S (en) Tablet
CA89993S (en) Tablet
GB0014451D0 (en) Pharmaceutical formulation
GB0014424D0 (en) Pharmaceutical formulation
GB0019084D0 (en) Pharmaceutical formulation
GB0018654D0 (en) Pharmaceutical formulation
GB0018686D0 (en) Pharmaceutical formulation
AU141868S (en) Tablet
GB0019840D0 (en) Novel pharmaceutical formulation
GB0002691D0 (en) Pharmaceutical composition